Lixte Biotechnology Holdings, Inc.
LIXT
$4.20
$0.143.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 181.64% | -10.55% | -27.40% | -34.00% | -30.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.20% | -23.23% | -26.89% | -40.20% | -3.99% |
| Operating Income | -83.20% | 23.23% | 26.89% | 40.20% | 3.99% |
| Income Before Tax | -100.85% | 23.27% | 26.94% | 40.16% | 3.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.85% | 23.27% | 26.94% | 40.16% | 3.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.85% | 23.27% | 26.94% | 40.16% | 3.22% |
| EBIT | -83.20% | 23.23% | 26.89% | 40.20% | 3.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 24.93% | 36.56% | 33.51% | 40.07% | 10.71% |
| Normalized Basic EPS | 26.79% | 36.56% | 33.53% | 40.08% | 10.72% |
| EPS Diluted | 24.93% | 36.56% | 33.51% | 40.07% | 10.71% |
| Normalized Diluted EPS | 26.79% | 36.56% | 33.53% | 40.08% | 10.72% |
| Average Basic Shares Outstanding | 174.36% | 20.95% | 9.88% | -0.16% | 8.41% |
| Average Diluted Shares Outstanding | 174.36% | 20.95% | 9.88% | -0.16% | 8.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |